A risk prediction model for acute kidney injury in patients with pulmonary tuberculosis during anti-tuberculosis treatment

Zhi Xiang Du, Fang Qun Chang, Zi Jian Wang, Da Ming Zhou, Yang Li and Jiang Hua Yang

Department of Infectious Diseases, Taizhou People’s Hospital, Taizhou, China; Department of Geriatric respiratory and critical illness, The First Affiliated Hospital of Anhui Medical University, Hefei, China; Department of Infectious Diseases, Yijishan Hospital, Wannan Medical College, Wuhu, China

ABSTRACT
Background: Acute kidney injury (AKI) is not a rare complication during anti-tuberculosis treatment in some patients with pulmonary tuberculosis (PTB). We aimed to develop a risk prediction model for early recognition of patients with PTB at high risk for AKI during anti-TB treatment.

Methods: This retrospective cohort study assessed the clinical baseline, and laboratory test data of 315 inpatients with active PTB who were screened for predictive factors from January 2019 to June 2020. The elements were analyzed by logistic regression analysis. A nomogram was established by the results of the logistic regression analysis. The prediction model discrimination and calibration were evaluated by the concordance index (C-index), ROC curve, and Hosmer-Lemeshow analysis.

Results: A total of 315 patients with PTB were enrolled (67 patients with AKI and 248 patients without AKI). Seven factors, including microalbuminuria, hematuria, cystatin-C (CYS-C), albumin (ALB), creatinine-based estimated glomerular filtration rates (eGFRs), body mass index (BMI), and CA-125 were acquired to develop the predictive model. According to the logistic regression, microalbuminuria (OR = 3.038, 95%CI 1.168–7.904), hematuria (OR = 3.656, 95%CI 1.325–10.083), CYS-C (OR = 4.416, 95%CI 2.296–8.491), and CA-125 (OR = 3.93, 95%CI 1.436–10.756) were risk parameter, while ALB (OR = 0.741, 95%CI 0.650–0.844) was protective parameter. The nomogram demonstrated good prediction in estimating AKI (C-index= 0.967, AUC = 0.967, 95%CI (0.941–0.984), sensitivity = 91.04%, specificity = 93.95%, Hosmer-Lemeshow analysis SD = 0.00054, and quantile of absolute error = 0.049).

Conclusions: Microalbuminuria, hematuria, ALB reduction, elevated CYS-C, and CA-125 are predictive factors for the development of AKI in patients with PTB during anti-TB treatments. The predictive nomogram based on five predictive factors is achieved good risk prediction for AKI during anti-TB treatments.

Abbreviations: CEA: carcinoembryonic antigen; CA-125: cancer antigen 125; CA19-9: cancer antigen19-9; BMI: body mass index; RBC: red blood cell; HB: hemoglobin; NE: neutrophile granulocyte; LYM: lymphocyte; MON: monocyte; PLT: blood platelet; USG: urine specific gravity; UCR: urine creatinine; Hematuria: URBC; TBIL: total bilirubin; DBIL: direct bilirubin; TP: total protein; ALB: albumin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: serum alkaline phosphatase; GGT: gamma-glutamyl transpeptidase; LDH: lactate dehydrogenase; CK: creatine kinase; ACE: angiotensin converting enzyme; HCY: homocysteine; BUN: urea nitrogen; CREA: creatinine; UA: uric acid; β2MG: β2-microglobulin; CYS-C: cystatin-C; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; T-SPOT: T-SPOT.TB; CD3⁺: CD3 T cells; CD4⁺: CD4 T cells; CD8⁺: CD8 T cells; CD16⁺: CD16 natural killer cells; CD56⁺: CD56 natural killer cells; CD19⁺: CD19 B cells; IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M; C3: complement 3; C4: complement 4; Statistical methods: independent sample t-test

CONTACT Zhi Xiang Du daniel615212950@126.com Department of Infectious Diseases, Taizhou People’s Hospital, Taizhou, China; Jiang Hua Yang yjhpath@163.com Department of Infectious Diseases, Yijishan Hospital, Wannan Medical College, Wuhu, Anhui 241001, China

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. Introduction

Tuberculosis (TB) is a common infectious disease with a long history in China and is still one of the top 10 causes of death worldwide. The death rate of TB is still higher than that of HIV. According to the WHO Global Tuberculosis Report, approximately 1.7 billion people are infected with *Mycobacterium tuberculosis* (*M. tuberculosis*), and 10 million people are diagnosed with TB each year worldwide [1]. Although modern chemotherapy has played a pivotal role in combating TB, adverse drug events limit the completion rate of treatment [2].

Acute kidney injury (AKI) is not a single disease entity, and it is defined as an abrupt decline in kidney function that occurs within 7 days or less. An epidemiological survey estimated that 2 million people worldwide die of AKI every year, whereas some patients with AKI are at increased risk of developing chronic kidney disease (CKD) [3]. The retrospective study indicated that AKI is usually observed in patients admitted to the intensive care unit (ICU), and half of all such AKI was septic AKI [4]. In other studies, only one-third of cases of AKI were hospital-acquired, and the rest were community-acquired. Through statistical verification, increased GFR and proteinuria are independent risk factors for AKI [5].

AKI generally occurs in patients with acute or chronic diseases. In ICU patients, the predominant etiological category of AKI is sepsis, and the most common causes of sepsis are gram-negative bacteria, and fungal, etc [6]. A 5-year retrospective study indicated that AKI is not a rare complication during anti-TB treatment in the elderly population [7]. Acute kidney injury (AKI), acute kidney disease (AKD), and chronic kidney disease (CKD) can form a process of continuous kidney injury. A diagnosis of AKI should evaluate the possible cause of persistent kidney injury. Several studies have confirmed that a hypersensitivity reaction induced by rifampin is the leading cause of AKI during anti-TB treatment. Serum creatinine usually increases within 2 months of anti-TB-treatment and returns to baseline within 3 months. At the same time, approximately 27% of patients with AKI will develop permanent kidney damage [8]. More importantly, AKI is asymptomatic, so screening and prediction of kidney injury during anti-TB treatment are essential.

Kidney Disease: Improving Global Outcomes (KDIGO) recommends stratified screening of AKI occurrence based on the exposed and susceptible factors. However, there are few instruments to predict the occurrence of AKI [3].

In recent years, risk prediction models have been increasingly used to estimate the probability of occurrence (diagnostic models) or outcomes (predictive models) of a particular disease [9]. In Guan Chen's study, predictive factors such as age, previous surgical history, and cardiac arrhythmia were used to establish a prediction model to predict cardiac surgery-associated acute kidney injury (CSA-AKI). This model can improve the identification of patients at high risk for AKI before cardiac surgery [10]. Machine learning was used to develop risk prediction models in recent study [11]. Unfortunately, no prediction models have been developed to predict the risk of AKI during anti-TB treatment.

This study divided patients with pulmonary tuberculosis (PTB) into two groups according to AKI occurrence during anti-TB treatment. Clinical baseline and laboratory data were compared to obtain the different factors and establish a prediction model. The aim of this study was to develop a risk prediction model to effectively assess the risk of AKI before anti-TB treatment to prevent renal injury.

2. Materials and methods

2.1. Study population

This article was a retrospective observational study. This study obtained approval from the Clinical Research Ethics Committee of Taizhou People’s Hospital TZRY-LL-AF/SQ-014-2.0 (protocol number KY201803901). All tuberculosis diagnoses and treatments for TB were conform to the ‘Guidelines for Diagnosing and Treating Tuberculosis (2001)’ [12].

A total of 724 individuals were enrolled at the Department of Infectious Diseases, Taizhou People’s Hospital, Jiangsu Province between January 2019 and June 2020. According to the inclusion and exclusion criteria, 52 patients with Multidrug-resistant TB, 128 patients with retreatments of PTB, 33 patients with tuberculous pleurisy, 12 patients with nontuberculosis mycobacteria patients and 184 patients with the underlying disease were excluded. Finally, 315 patients with primary PTB were eventually enrolled in the statistical comparison (Figure 1).

Inclusion criteria: 1. According to the WHO guidelines, all patients with PTB had typical imaging lesions, positive sputum smears, or positive sputum cultures of *Mycobacterium tuberculosis*; 2. Acute kidney injury (AKI) was diagnosed by the KDIGO criteria established in 2012, serum creatinine increase \( \geq 0.3 \text{mg/dl} \) \( \geq 26.5 \text{µmol/L} \) within 48 h, or serum creatinine increase \( \geq 50\% \) from the baseline value within 7 days or duration of decrease in urine output (urine volume \( < 0.5 \) \( \geq 6 \text{h} \) [13].
Exclusion criteria: 1. Patients who had received anti-TB treatment before admission; 2. Patients diagnosed with multidrug-resistant TB, tuberculous pleurisy, retreatment of PTB, and nontuberculous mycobacterial infection; 3. PTB Patients who had underlying diseases such as hypertension, diabetes, immune diseases, kidney diseases, malignant tumors, viral hepatitis etc were excluded from enrollment.

All patients with active PTB were given standardized anti-TB treatment consisting of oral rifampicin (R) 10 mg/kg/d, isoniazid (H) 5 mg/kg/d, pyrazinamide (Z) 25 mg/kg/d, and ethambutol (E) 20 mg/kg/d for 2 months, followed by daily isoniazid and rifampicin for 4 months (2HRZE/4HR). The regimen was modified by the infectious disease physician, if necessary, when there were adverse drug effects.

2.2. Data Collection and study design

The enrolled patients were divided into two groups, the AKI-group: PTB with AKI and the control group, PTB without AKI.

The different factors were obtained from the clinical baseline and laboratory test data of the two groups. The clinical baseline included age, sex, occupation, residence, and lung imaging characteristics, etc. Laboratory test data included routine urine (PH value, UM/urine microalbumin, URBC/hematuria, etc.); Blood routine (RBC, NEU, etc.); liver function (TBIL, ALB, ALT, AST, etc.) and kidney function (BUN, CREA, UA, B2MG, CYS-C, etc.). Tumor and inflammatory indicators were also included in the laboratory test data. The CA-125, CEA, and CA19-9 cutoff points were selected to be 22 U/ml, 5.0 ng/ml, and 37 U/L, respectively. The liver and kidney function tests were reviewed within 7 days after anti-TB treatment.

The predictive factors for AKI in patients with PTB during anti-TB treatment were analyzed by logistic regression analysis. A prognostic nomogram was established with the results of the logistic regression analysis.

The immunological indices of the two groups were compared to explore the possible immunological mechanisms of AKI. Abbreviations in the text are explained in the Abbreviations section.

2.3. Statistical analysis

The data were expressed as the frequencies (n), percentages (%), means ± standard deviations (SDs), and
median (interquartile ranges) and were analyzed with R version 4.0.2. Count data were analyzed with the chi-square test. If measurement data conformed to a normal distribution, the t-test was used to analysis. The Mann–Whitney U-test was used to compare non-normally distributed data. Before regression analysis, the factors were verified by multiple linear regression to verify independence. Continuous variables (CYS-C ALB, eGFR, and BMI) were substituted into the model according to covariates; categorical variables (UM, URBC, and CA-125) were substituted into the model according to categorical covariates. The nomogram was constructed based on the results of the logistical regression results using the rms package in R software. The discrimination of the prediction model was verified by the C-index and the receiver-operating characteristic curve (ROC curve). The calibration curve verified the correctness of the prediction model. p < .05 was considered statistically significant.

### 3. Results

#### 3.1. Characteristics of clinical baseline data

A total of 315 patients who received initial treatment for pulmonary tuberculosis patients (PTB) were enrolled in this study. 67 (21.27%) patients with PTB who had acute kidney injury were included in the AKI group, and 248 (78.73%) patients with PTB who did not have AKI were included in the control group; There was no significant difference between the two groups in age, sex, occupation, or the extent of lesion involvement (p > .05);

The average BMI in the control group was 19.99 ± 2.82 kg/m2, which was significantly higher than that in the AKI group 17.90 ± 2.39 kg/m2(p < .05); The positive proportion accounted for CA-125 was 35.89% in the control group, which was significantly lower than that in the AKI group 83.87% (p < .05); There was no significant difference in T-SPOT, CEA, CA199, CRP, or ESR between the two groups (Table 1).

#### Table 1. The clinical baseline data of PTB patients.

| Variable          | Control Group | AKI Group | Total | Statistics($\chi^2$/t/z) | p-value |
|-------------------|---------------|-----------|-------|--------------------------|---------|
| n                 | 248(78.73%)   | 67(21.27%)| 315   |                          |         |
| Age(year)         | 56.68 ± 18.77 | 58.36 ± 19.22 | 57.03 ± 18.85 | 0.647 | .518 |
| Sex               |               |           |       |                          |         |
| Male              | 182(73.39%)   | 51(76.12%)| 233(73.97%) | 0.205 | .754 |
| Female            | 66(26.61%)    | 16(23.88%)| 82(26.03%) |          |       |
| BMI(kg/m²)        | 19.99 ± 2.82  | 17.90 ± 2.39 | 18.95 ± 2.61 | 5.544 | <.001 |
| Occupation        |               |           |       |                          |         |
| Individual        | 5(2.02%)      | 11(4.99%) | 16(5.07%) | 11.659 | .234 |
| Worker            | 17(6.85%)     | 3(4.48%)  | 20(6.35%) | 20(6.35%) | .398 |
| Medical staff     | 3(0.81%)      | 1(1.49%)  | 4(1.25%)  | 4(1.25%) | .139 |
| Farmer            | 56(22.58%)    | 15(22.39%)| 71(22.34%) | 71(22.34%) | .117 |
| Retirement        | 61(24.60%)    | 20(29.85%)| 81(25.71%) | 81(25.71%) | .117 |
| Student           | 13(5.24%)     | 11(4.49%) | 24(7.66%) | 24(7.66%) | .117 |
| Staff             | 40(16.13%)    | 6(8.96%)  | 46(14.60%) | 46(14.60%) | .117 |
| Free              | 114(44.4%)    | 12(13.43%)| 126(39.89%) | 126(39.89%) | .117 |
| Other             | 4(1.61%)      | 2(1.49%)  | 6(1.90%)  | 6(1.90%) | .117 |
| Unemployed        | 37(14.92%)    | 19(28.36%)| 56(17.78%) | 56(17.78%) | .117 |
| Lesion site       |               |           |       |                          |         |
| Two lungs         | 182(80.6%)    | 54(80.6%) | 236(74.92%) | 236(74.92%) | .117 |
| Left lung         | 26(5.97%)     | 4(5.97%)  | 30(9.52%) | 30(9.52%) | .117 |
| Right lung        | 40(13.43%)    | 9(13.43%) | 49(15.56%) | 49(15.56%) | .117 |
| T-SPOT(+)         | 142(57.26%)   | 42(62.69%)| 184(58.41%) | 184(58.41%) | .117 |
| T-SPOT(–)         | 106(42.74%)   | 25(37.31%)| 131(41.59%) | 131(41.59%) | .117 |
| CEA(+)            | 12(10.45%)    | 7(10.45%) | 19(6%)  | 19(6%) | .117 |
| CEA(–)            | 236(89.55%)   | 60(89.55%)| 296(96.97%) | 296(96.97%) | .117 |
| CA-125(+)         | 89(35.89%)    | 52(82.87%)| 141(44.76%) | 141(44.76%) | .117 |
| CA-125(–)         | 159(64.11%)   | 15(16.13%)| 174(55.24%) | 174(55.24%) | .117 |
| CA19-9(+)         | 39(19.40%)    | 13(19.40%)| 52(16.51%) | 52(16.51%) | .117 |
| CA19-9(–)         | 209(80.60%)   | 54(80.60%)| 263(83.49%) | 263(83.49%) | .117 |
| CRP(mg/l)         | 19.23 (3.18–46.94) | 47.23 (11.73–86.54) | 23.86 (5.11–54.04) | 23.86 (5.11–54.04) | .117 |
| ESR(mm/h)         | 32.68 ± 30.38 | 48.92 ± 34.70 | 40.08 ± 32.54 | 40.08 ± 32.54 | .117 |

CEA: carcinoembryonic antigen; CA-125: cancer antigen 125; CA19-9: cancer antigen 19-9; T-SPOT: T-SPOT.TB; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; BMI: body mass index. Statistical method: chi-square test, t-test, Mann-Whitney U-test.
3.2. Characteristics of routine blood and urine tests

The positive proportion of microalbuminuria (UM) was 17.74% in the control group, which was significantly lower than that in the AKI group 61.19% (p < 0.05). The number of patients with hematuria in the control group was 26 (10.48%), which was significantly lower than 33(49.25%) in the AKI group (p < 0.05) (Table 2).

3.3. Characteristics of liver and kidney function tests

With regard to liver and kidney function tests, the ALB level in the AKI group was 28.94 ± 3.46 g/l, which was significantly lower than 35.17 ± 4.8 g/l in the control group (p < 0.05); The level of CYS-C in the AKI group was 1.66 ± 0.51 mg/l, which was significantly higher than 0.8 ± 0.43 mg/l in the control group (p < 0.05); The eGFR level in the AKI group was 83.50 ± 36.98 ml/min per 1.73m², which was lower than 94.61 ± 35.34 ml/min per 1.73m² in the control group; There was no significant difference in other indices between the two groups (Table 3).

3.4. The renal function characteristics of PTB-AKI patients before and after treatment

In 67 patients with AKI-TB, the five renal functions BUN, CREA, UA, B2MG, and CYS-C, were significantly increased after anti-TB treatment compared with before treatment (Table 4).

3.5. Independence verification of different factors

Seven different factors were obtained through the above comparison. Spearman’s correlation analysis was

Table 2. The characteristics of blood routine and urine routine in PTB patients.

| Variable   | Control Group | AKI Group | Total | Statistics (χ²/t/z) | p-value |
|------------|---------------|-----------|-------|--------------------|---------|
| n          | 248 (78.73%)  | 67 (21.27%) | 315   |                    |         |
| RBC (10^9/L) | 4.22 ± 2.43   | 3.89 ± 0.71 | 4.148 ± 2.186 | 1.080 | .281               |
| HB (g/L)   | 118.54 ± 21.23| 122.58 ± 19.45 | 120.56 ± 20.34 | 1.406 | .161               |
| NEU (10^9/L)| 5.9 ± 2.59    | 5.55 ± 2.18 | 5.99 (0.73–1.44) | 1.814 | .700               |
| LYM (10^9/L)| 1.025 (0.74–1.15)| 0.95 (0.62–1.25) |         |             |
| MON (10^9/L)| 0.52 (0.37–1.5)| 0.55 (0.39–0.83) | 0.52 (0.37–0.72) | 0.829 | .407               |
| PLT (10^9/L) | 232.5 (182.00–303.00)| 219.00 (171.00–327.00) | 232.00 (178.00–307.00) | 0.100 | .921               |
| USG        | 1.02 (1.013–1.025)| 1.02 (1.015–1.025) | 1.02 (1.014–1.025) | 0.680 | .497               |
| UM         | 6.24 ± 0.7    | 6.16 ± 0.72 | 6.22 ± 0.706 | 0.856 | .393               |
| (+)        | 44 (17.74%)   | 41 (61.19%) | 85 (26.98%) |        |                  |
| (−)        | 204 (82.26%)  | 26 (38.81%) | 230 (73.02%) |        |                  |
| UCR (g/L)  | 1.00 (0.5–4.4)| 1.00 (1.00–5.00) | 1.00 (0.5–4.4) | 1.146 | .252               |
| Hematuria  | 52.088        | <.001     |        |        |                  |
| (+)        | 26 (10.48%)   | 33 (49.25%) | 59 (18.73%) |        |                  |
| (−)        | 222 (89.52%)  | 34 (50.75%) | 256 (81.25%) |        |                  |

RBC: red blood cell; HB: hemoglobin; NEU: neutrophile granulocyte; LYM: lymphocyte; MON: monocyte; PLT: blood platelet; USG: Urine specific gravity; UM: microalbuminuria; UCR: Urine creatinine. Statistical methods: independent sample t-test, nonparametric test, chi-square test.

Table 3. The characteristics of liver and kidney function in PTB patients.

| Variable   | Control Group | AKI Group | Total | Statistics (t/z) | p-value |
|------------|---------------|-----------|-------|------------------|---------|
| N          | 248 (78.73%)  | 67 (21.27%) | 315   |                  |         |
| TBIL (umol/L) | 10.15 (7.60–13.25)| 10.30 (8.10–13.10) | 10.30 (7.70–13.10) | 1.001 | .317               |
| DBIL (umol/L) | 2.62 ± 1.11   | 2.89 ± 0.94 | 2.76 ± 1.03 | 1.829 | .069               |
| TP (g/L)   | 66.34 ± 9.31  | 65.63 ± 12.33 | 66.19 ± 10.01 | 0.511 | .609               |
| ALB (g/L)  | 35.17 ± 4.8  | 28.94 ± 3.46 | 33.85 ± 5.21 | 4.959 | <.001               |
| ALT (U/L)  | 12.00 (8.00–20.00) | 12.00 (8.00–20.00) | 12.00 (8.00–20.00) | 0.467 | .641               |
| AST (U/L)  | 22.04 ± 10.6 | 22.31 ± 8.09 | 22.18 ± 8.36 | 0.829 | .407               |
| ALP (U/L)  | 95.27 ± 37.12 | 104.61 ± 56.09 | 97.62 ± 41.96 | 1.621 | .106               |
| GGT (U/L)  | 24.00 (16.00–24.00)| 25.00 (18.00–46.00) | 24.00 (17.00–42.00) | 1.612 | .107               |
| LDH (U/L)  | 183.03 ± 48.28| 193.31 ± 71.56 | 185.22 ± 54.35 | 1.376 | .170               |
| CK (U/L)   | 42.5 (30.00–65.75)| 41.00 (28.00–83.00) | 42.00 (30.00–66.00) | 0.499 | .618               |
| ACE (U/L)  | 31.89 ± 12.62 | 33.14 ± 17.25 | 32.21 ± 13.72 | 0.800 | .424               |
| HCY (umol/L) | 12.21 ± 5.59  | 14.2 ± 11.13 | 12.63 ± 7.16 | 2.030 | .161               |
| BUN (mmol/L) | 4.81 ± 2.00   | 5.26 ± 2.58 | 4.91 ± 2.14 | 1.544 | .124               |
| CREA (umol/L) | 63.81 ± 29.87 | 69.73 ± 54.60 | 65.07 ± 36.52 | 1.179 | .239               |
| UA (umol/L) | 287.87 ± 108.07 | 269.62 ± 96.54 | 283.99 ± 105.84 | 1.253 | .184               |
| β2MG (mg/L) | 2.38 ± 0.83   | 2.48 ± 0.82 | 2.43 ± 0.83 | 0.894 | .372               |
| CYS-C (mg/L) | 0.8 ± 0.43    | 1.66 ± 0.51 | 0.98 ± 0.57 | 1.140 | <.001               |
| eGFR (ml/min per 1.73m²) | 94.61 ± 35.34 | 83.50 ± 36.98 | 89.06 ± 36.16 | 2.259 | .025               |

TBIL: total bilirubin; DBIL: direct bilirubin; TP: total protein; ALB: albumin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ALP: serum alkaline phosphatase; GGT: gamma-glutamyl transpeptidase; LDH: lactate dehydrogenase; CK: creatine kinase; ACE: angiotensin converting enzyme; HCY: homocysteine; BUN: urea nitrogen; CREA: creatinine; UA: uric acid; β2MG: β2-microglobulin; CYS-C: cystatin-C; eGFR: estimated glomerular filtration rate. Statistical methods: independent sample t-test, nonparametric test.
used to verify the independence of the seven factors (Figure 2). In the positive correlations, the correlation between BMI and ALB was the highest ($r = 0.41$); in the negative correlations, the correlation between ALB and CYS-C was the highest ($r = -0.36$). The correlation between all variables was low, ($r < \pm 0.5$). Four continuous variables (BMI, CYS-C, ALB, and eGFR) were independent of each other (Table 5). There was no significant multicollinearity between the four continuous variables (VIF < 5, $R^2 < 1$).

### 3.6. Logistic regression analysis of the different factors between the two groups

To determine the predictors for AKI incidence in patients with PTB during anti-TB treatments, seven parameters (microalbuminuria, hematuria, CYS-C, ALB, eGFR, BMI, and CA-125) were included in the binary logistic regression.

According to the OR, four parameters were high-risk factors for AKI in patients with PTB during anti-TB treatments: UM-microalbuminuria (OR = 3.038, 95%CI 1.168–7.904), URBC-hematuria (OR = 3.656, 95%CI 1.325–10.083), CYS-C (OR = 4.416, 95%CI 2.296–8.491), and CA-125 (OR = 3.93, 95%CI 1.436–10.756). On the

### Table 4. The characteristics of the renal function of PTB-AKI patients before and after treatment.

| Values | Before-T | After-T | Statistics(t) | p-value |
|--------|----------|---------|---------------|---------|
| N      | 67       | 67      |               |         |
| BUN (mmol/L) | 5.26 ± 2.58 | 10.61 ± 5.00 | 9.107        | < .001  |
| CREA (umol/L)  | 69.74 ± 54.60 | 168.88 ± 104.83 | 11.698      | < .001  |
| UA (umol/L)  | 269.62 ± 96.54 | 457.94 ± 136.32 | 9.637      | < .001  |
| $\beta_2$MG (mg/L) | 2.48 ± 0.82  | 6.34 ± 8.03  | 3.899     | < .001  |
| CYS-C (mg/L)  | 1.66 ± 0.51  | 2.15 ± 0.53  | 2.638  | < .001  |

BUN: urea nitrogen; CREA: creatinine; UA: uric acid; $\beta_2$MG: $\beta_2$-microglobulin; CYS-C: cystatin-C; Before-T: Before treatment; After-T: After treatment. Statistical methods: iPaired sample t-test.

### Table 5. The result of multicollinearity analysis.

| Factors | $U$ Std. Coefficients | Std. Coefficients | Statistics | $R^2$ | Durbin-Watson |
|---------|----------------------|------------------|------------|------|---------------|
| BMI     | $-0.024$ | $0.006$ | $-0.167$ | $0.875$ | $1.143$ | $0.479$ | $0.908$ |
| CYS-C   | $0.190$  | $0.019$ | $0.437$ | $0.862$ | $1.160$ |
| ALB     | $-0.028$ | $0.003$ | $-0.351$ | $0.910$ | $1.099$ |
| eGFR    | $0.000$  | $0.000$ | $-0.020$ | $0.922$ | $1.084$ |

$U$ Std. Coefficients: Unstandardized Coefficients; Std. Coefficients: Standardized Coefficients; Tol: tolerance; VIF: variance inflation factor; eGFR: estimated glomerular filtration rate; CYS-C: cystatin-C. Statistical methods: Multicollinearity analysis.

![Figure 2](image.png)

Figure 2. Independence verification of different factors (UM: microalbuminuria; URBC: Hematuria; CYS-C: cystatin C; BMI: body mass index).
other hand, ALB (OR = 0.741, 95%CI 0.650–0.844) was a
protective parameter against the development of AKI (Table 6).

The risk of AKI in patients with PTB during anti-TB
treatments was calculated by the following the binary
logistic regression equation: \( \ln(p/(1-p)) = 8.244 + 1.111 \) (with microalbuminuria) + 1.296* (with Hematuria) + 1.485* (CYS-C value) + 1.369* (with positive CA-125) − 0.3* (ALB value). In the equation, \( p \) represents the probability of AKI in patients with PTB during anti-TB treatments.

3.7. Nomogram construction and validation
A prognostic nomogram for the early recognition of AKI
in patients with PTB before anti-TB treatment was con-
structed using the binary logistic regression results, and

Table 6. Logistic regression analysis of the difference factors.

| Factors | B     | S.E  | Wald/2 | p-value | OR    | 95%CI  |
|---------|-------|------|--------|---------|-------|--------|
| UM      | 1.111 | 0.488| 5.187  | .023    | 3.038 | 1.168–7.904 |
| URBC    | 1.296 | 0.518| 6.271  | .012    | 3.656 | 1.325–10.083 |
| CYS-C   | 1.485 | 0.334| 19.821 | .000    | 4.416 | 2.296–8.491 |
| ALB     | −0.3  | 0.067| 20.243 | .000    | 0.741 | 0.650–0.844 |
| eGFR    | −0.012| 0.007| 2.791  | .095    | 0.989 | 0.975–1.002 |
| BMI     | −1.335| 0.102| 1.74   | .187    | 0.874 | 0.716–1.068 |
| CA-125  | 1.369 | 0.514| 7.097  | .008    | 3.93  | 1.436–10.756 |

BMI: body mass index; UM: microalbuminuria; URBC: Hematuria; eGFR: estimated glomerular filtration rat; CA-125: cancer antigen 125; OR: odds ratio; CI: confidence interval. Statistical methods: Binary logistics regression analysis.

To evaluate the discrimination of the prediction
model, the C-index was calculated by the bootstrapping
technique. The predicted values of the model plotted
the ROC curve. The C-index was 0.967, and the AUC of
the ROC curve was \( \text{AUC} = 0.967, (95\% \text{CI} = 0.941–0.984) \)
Youden index \( J = 0.850, \) sensitivity was 91.04%, specifici-
city was 93.95% (Figure 4).

To evaluate the calibration of the prediction model,
the calibration curve was plotted by Hosmer-Lemeshow
analysis. The prediction model had good calibration
(Figure 5).

3.8. Characteristics of immunological data of 63
patients with PTB
The immunological data of 19 patients with PTB who
had AKI and 49 patients with PTB who did not had AKI
were measured in this study. The numbers of CD3 T
cells in the AKI group were significantly higher than
those in the control group; CD4⁺ T cell/CD8⁺ T cell in the AKI group were significantly higher than those in the control group. The values of IgG and IgA in the AKI group was also significantly higher than those in the control group (p < .05) (Table 7).

4. Discussion

Acute kidney injury (AKI) is not a rare complication during anti-TB treatment in some special populations [7]. Renal function impairment that fails to recover within 7 days will progress to acute kidney disease (AKD) [14]. Therefore, the prediction model to identify the risk for AKI is significant.

Chronic diseases such as diabetes, hypertension, and viral hepatitis are common causes of damage to kidney function [15]. More importantly, diabetes mellitus is a significant risk factor for latent TB [16]. A total of 184 patients with PTB who had an underlying disease were not included in our study to avoid mixed effects. After comparing the clinical data of 371 patients with PTB, seven factors (microalbuminuria, hematuria, CYS-C, albumin, eGFR, BMI, and CA-125) were acquired to develop the predictive model. The independence of factors is verified before the logistic analysis. According to the binary logistic regression analysis, four parameters (microalbuminuria, hematuria, CYS-C, and CA-125) were high-risk factors for AKI in patients with PTB during anti-TB treatments, while ALB was a protective parameter against the development of AKI.

As an endogenous inhibitor of cysteine proteinases, CYS-C plays an essential role in controlling protease activity in immune system regulation, and antiviral, and...
antimicrobial activities. Eventually, CYS-C is partially reabsorbed and decomposed in proximal tubular cells [17, 18]. In this study, there was a relatively large dissociation between creatinine and CYS-C. These results indicated that, in the early stages of kidney injury, compared with serum creatinine or eGFR, CYS-C has a higher sensitivity to predict early renal damage.

Although studies have confirmed that the value of CA-125 is related to the severity of PTB [19], serum CA-125 is beneficial in the differentiation between active and inactive PTB [20]. However, the mechanism of CA-125 elevation after TB infection is still unclear. Previous studies have confirmed that CA-125 is associated with most mesothelial membranes. CA-125 can also bind to the mesothelial cell surface glycoprotein mesothelin, indicating a potential role in cell adhesion in health and disease [21]. We believe that the level of CA-125 can reflect the degree of inflammation caused by TB.

TB can lead to malnutrition, and poor nutritional status may predispose individuals to TB. ALB and BMI are direct indicators that reflect the nutritional status of patients. Cell-mediated immunity is the critical host defense against M. tuberculosis. Malnutrition is a significant risk factor for immune system abnormalities in patients with TB [22]. Both innate resistant and adaptive immune cells play specific roles in the development of AKI [23]. Consequently, severely malnourished patients with TB have a higher risk for developing AKI.

Urine microalbumin is considered an important marker of preclinical nephropathy [24]. In this study, approximately 50% of patients with PTB who had AKI had hematuria before anti-TB treatment [25,26]. After comparing the immunological indices, we confirmed that patients with PTB who had AKI had high numbers of CD3⁺ T cells. The values of CD4⁺T cell/CD8⁺ T cell, IgG, and IgA in the AKI group were significantly higher than those in the control group. The natural infection process of M. tuberculosis is complex. First, M. tuberculosis invades alveolar macrophages, replicates in macrophages, spreads to macrophages, myeloid dendritic cells, and neutrophils recruited from the surrounding areas, and finally triggers adaptive immunity [27]. The tubercle bacillus produces excessive tumor necrosis factor after infection and has extreme mitochondrial reactive oxygen species (ROS) through the mitochondrial-endoplasmic reticulum circuit, triggering the programmed necrosis of macrophages. AKI is associated with increased oxidative damage [28]. Superoxide radical anions, peroxides, and hydroxyl radicals can oxidize biomolecules and membranes, affect organelle function, and eventually induce renal tubular cell injury [29]. Active TB is frequently associated with a substantial increase in serum IgA levels. In addition, the ratio of T cells is positively correlated with serum IgA levels. The deposition of immune complexes in the kidney leads to renal dysfunction [30].

Confusingly, we do not yet know the exact cause of AKI in patients with PTB, whether the deposition of immune complexes produced by TB infection damages the glomerulus, whether anti-TB drugs (such as rifampicin) can cause tubular or interstitial damage, or whether both play an essential role is unknown. At present, we can make it clear that some patients with PTB have a higher risk of AKI during anti-TB treatment, and nephrotoxic drugs and special tests (such as coronary angiography) need to be avoided [31].

Nomograms were introduced to the medical field by J.L. Henderson in 1928. Nomograms can be used to predict the probability of the outcome of the regression model [32]. As shown in the nomogram plot (Figure 3), patients with PTB who had microalbuminuria, hematuria, and a higher value of CYS-C, and CA-125 were more likely to develop AKI during anti-TB treatment. Nevertheless, patients with PTB who had higher ALB levels were at a lower risk of developing AKI. By summing the total score and locating the score on the full

| Variable | Control Group | AKI Group | Total | Statistics(t) | p-value |
|----------|---------------|-----------|-------|---------------|---------|
| n        | 49            | 19        | 68    |               |         |
| CD3⁺     | 66.07 ± 14.06 | 73.15 ± 10.01 | 68.05 ± 13.37 | 2.004 | .049    |
| CD3⁻/CD8⁻| 24.22 ± 9.31  | 25.15 ± 12.04  | 24.48 ± 10.06  | 0.339 | .735    |
| CD3⁻/CD4⁻| 39.26 ± 13.49 | 45.58 ± 14.48  | 41.03 ± 13.96  | 1.697 | .094    |
| CD16⁻/CD56⁻| 14.22 ± 9.22 | 13.60 ± 9.22 | 14.05 ± 9.46 | 0.242 | .809 |
| CD19⁺     | 11.81 ± 7.13  | 8.49 ± 5.80   | 10.68 ± 6.90   | 1.807 | .075    |
| CD4⁺/CD8⁺ | 2.00 ± 1.14   | 3.16 ± 1.73   | 2.32 ± 1.42    | 3.230 | .002    |
| IgG       | 11.49 ± 2.76  | 19.15 ± 11.91 | 13.63 ± 7.46 | <.001 |         |
| IgA       | 2.36 ± 0.91   | 3.02 ± 1.4    | 2.54 ± 1.10    | 2.295 | .025    |
| IgM       | 1.01 ± 0.43   | 1.08 ± 0.73   | 1.03 ± 0.52    | 0.460 | .647    |
| C3        | 1.03 ± 0.23   | 0.95 ± 0.24   | 1.00 ± 0.23    | 1.295 | .200    |
| C4        | 0.26 ± 0.09   | 0.23 ± 0.07   | 0.25 ± 0.09   | 1.113 | .270    |

CD3⁺: CD3 T cells; CD4⁺: CD4 T cells; CD8⁻: CD8 T cells; CD16⁻: CD16 natural killer cells; CD56⁻: CD56 natural killer cells; CD19⁻: CD19 B cells; IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M; C3: complement 3; C4: complement 4. Statistical methods: independent sample t-test.
point scale, the development of AKI can be predicted for patients with PTB before anti-TB treatment. Patients with PTB who had a total score of 132 have a 50% risk of developing AKI after anti-TB treatment. ROC curve and Hosmer-Lemeshow analyses were used to evaluate the prediction model discrimination and calibration of the prediction model. According to the analysis mentioned above, we believe that the initial treatment of patients with PTB who had malnutrition, microalbuminuria, hematuria, CA-125 positivity, and a high CYS-C value should not receive anti-TB immediately, supposing patients with PTB fail to improve their nutritional status and fail take measures to protect their kidney function in advance. In that case, they have a greater risk of AKI after the start of anti-TB treatment.

5. Limitations
In this study, the proportion of AKI in patients with PTB was higher than that reported in relevant clinical studies. The individuals included in our study were hospitalized patients with more severe pulmonary lesions, leading to statistical bias. This study failed to collect the long-term outcomes of patients with AKI, and the relevant factors affecting the long-term effects of patients will be statistically verified in the future. The mechanism of AKI in patients with PTB needs to be further studied to provide a theoretical basis for clinical prevention and treatment.

6. Conclusions
Microalbuminuria, hematuria, ALB, elevated CYS-C, and CA-125 positivity are predictive factors for AKI in patients with PTB during anti-TB treatments. Through the predictive nomogram based on five predictive factors, the risk of AKI in patients with PTB during anti-TB treatments can be determined earlier. Such an application is helpful for timely intervention to improve the patient’s prognosis.

Ethical approval
All subjects were treated with standard care without intervention from this study. All data were obtained via electronic medical records and a database review and were acquired (the patient’s name was replaced with an identification code, and the patient’s private information was deleted before the analysis) to protect patient privacy. This study obtained approval from the Clinical Research Ethics Committee of Taizhou People’s Hospital TZRY-LL-AF/SQ-014-2.0 (Protocol number KY2018003901). The informed consent of human clinical data was obtained from all subjects.

Acknowledgements
The authors thank Dr. Yang Jianghua for his guidance on the design and writing of this paper.

Disclosure statement
The authors declared no competing interests.

Funding
The author(s) reported there is no funding associated with the work featured in this article.

Data availability statements
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

References
[1] WHO. Global tuberculosis report 2020. 2020.
[2] Borisov S, Maryandysev DE. A Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. Eur Respir J. 2019;54(6):1901522.
[3] Levey AS, James MT. Acute kidney injury. Ann Intern Med. 2017;167(9):ITC66–ITC80.
[4] Bellomo R, Kellum JA, Ronco C, et al. Acute kidney injury in sepsis. Intensive Care Med. 2017;43(6):816–828.
[5] Wang Y, Wang J, Su T, ISN AKF 0by25 China Consortium, et al. Community-acquired acute kidney injury: a nationwide survey in China. Am J Kidney Dis. 2017;69(5):647–657.
[6] Evans RDR, Hemmilä U, Craik A, et al. Incidence, aetiology and outcome of community-acquired acute kidney injury in medical admissions in Malawi. BMC Nephrol. 2017;18(1):21.
[7] Chang C-H, Chen Y-F, Wu V-C, et al. Acute kidney injury due to anti-tuberculosis drugs: a five-year experience in an aging population. BMC Infect Dis. 2014;14:23.
[8] Sakashita K, Murata K, Takahashi Y, et al. A case series of acute kidney injury during anti-tuberculosis treatment. Intern Med. 2019;58(4):521–527.
[9] Hendriksen JMT, Geersing GJ, Moons KGM, et al. Diagnostic and prognostic prediction models. J Thromb Haemost. 2013;11(Suppl 1):129–141.
[10] Guan C, Li C, Xu L, et al. Risk factors of cardiac surgery-associated acute kidney injury: development and validation of a perioperative predictive nomogram. J Nephrol. 2019;32(6):937–945.
[11] Huang C, Murugiah K, Mahajan S, et al. Enhancing the prediction of acute kidney injury risk after percutaneous coronary intervention using machine learning techniques: a retrospective cohort study. PLoS Med. 2018;15(11):e1002703.
[12] Association CM Guidelines for the diagnosis and treatment of tuberculosis. Chinese Journal of Tuberculosis and Respiratory Diseases. 2001;24(2):1001–0939.

[13] KDIGO. KDIGO Clinical Practice Guideline for Acute Kidney Injury. 2012.

[14] Schetz M, Prowle J. Focus on acute kidney injury 2017. Intensive Care Med. 2018;44(11):1992–1994.

[15] Shah AS, Amarapurkar DN. Spectrum of hepatitis B and renal involvement. Liver Int. 2018;38(1):23–32.

[16] Rhee CM, Kalantar-Zadeh K. Diabetes mellitus: complex interplay between metformin, AKI and lactic acidosis. Nat Rev Nephrol. 2017;13(9):521–522.

[17] Onopiuk A, Tokarzewicz A, Gorodkiewicz E. Cystatin C: a kidney function biomarker. Adv Clin Chem. 2015;68:57–69.

[18] van der Laan SW, Fall T, Soumaré A, et al. Cystatin C and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2016;68(9):934–945.

[19] Du Z-X, Liang M-M, Sun J, et al. Clinical significance of serum CA-125, CA19-9 and CEA in pulmonary tuberculosis with and without type 2 diabetes. Tuberculosis (Edinb). 2017;107:104–110.

[20] Yilmaz A, Ece F, Bayramgüler B, et al. The value of CA 125 in the evaluation of tuberculosis activity. Respir Med. 2001;95(8):666–669.

[21] Bast RC, Jr., Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005;15(Suppl 3):274–281.

[22] Kant S, Gupta H, Ahluwalia S. Significance of nutrition in pulmonary tuberculosis. Crit Rev Food Sci Nutr. 2015;55(7):955–963.

[23] Jin H, Zhang Y, Ding Q, et al. Epithelial innate immunity mediates tubular cell senescence after kidney injury. JCI Insight. 2019;4(2):e125490.

[24] Moreno JA, Sevillano A, Gutierrez E, et al. Glomerular hematuria: Cause or consequence of renal inflammation? Int J Mol Sci. 2019;20(9):2205.

[25] Isobe S, Yuba M, Mori H, et al. Increased pre-procedural urinary microalbumin is associated with a risk for renal functional deterioration after coronary computed tomography angiography. Int J Cardiol. 2017;230:599–603.

[26] Linder BJ, Bass EJ, Mostafid H, et al. Guideline of guidelines: asymptomatic microscopic haematuria. BJU Int. 2018;121(2):176–183.

[27] Ayeleign B, Negash M, Genetu M, et al. Immunological impacts of diabetes on the susceptibility of Mycobacterium tuberculosis. J Immunol Res. 2019;2019:6196532.

[28] Roca FJ, Whitworth LJ, Redmond S, et al. TNF induces pathogenic programmed macrophage necrosis in tuberculosis through a mitochondrial-lysosomal-endoplasmic reticulum circuit. Cell. 2019;178(6):1344–1361.

[29] Dennis JM, Witting PK. Protective role for antioxidants in acute kidney disease. Nutrients. 2017;9(7):718.

[30] Wang Y, Tao Y. Tuberculosis-associated IgA nephropathy. J Int Med Res. 2018;46(7):2549–2557.

[31] McCullough PA, Choi JP, Feghali GA, et al. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2016;68(13):1465–1473.

[32] Touijer K, Scardino PT. Nomograms for staging, prognosis, and predicting treatment outcomes. Cancer. 2009;115(13 Suppl):3107–3111.